Form 4: Plus Therapeutics CEO Granted Stock Options

CEO of Plus Therapeutics, Marc Hedrick, was granted stock options on February 18, 2025.

Summary

• Marc H. Hedrick, CEO of Plus Therapeutics, was granted stock options on February 18, 2025.
• The options allow him to purchase 400,489 shares of common stock at an exercise price of $1.18 per share.
• The options vest in equal monthly installments over four years, starting on the monthly anniversary of the grant date.
• The options expire on February 17, 2035.

Sentiment

Score: 7

Explanation: The granting of stock options is generally viewed positively as it aligns management interests with shareholders, but it also represents potential dilution.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant and vesting schedule are typical for a CEO of a company with a similar market capitalization to Plus Therapeutics.
• Comparable companies such as Celldex Therapeutics and Northwest Biotherapeutics also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders may experience dilution if the options are exercised.
• The CEO is incentivized to increase shareholder value through the stock option grant.

Key Dates

Keywords

stock options, CEO, Plus Therapeutics, PSTV, Marc Hedrick, equity compensation, Form 4